BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Warren Fiskus, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan, Christopher P. Mill, Christine E. Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Antrix Jain, Anna Malovannaya, Tapan M. Kadia, Naval Daver, Koji Sasaki, Koichi Takahashi, Danielle Hammond, Patrick K. Reville, Jian Wang, Sanam LoghaviRwik Sen, Xinjia Ruan, Xiaoping Su, Lauren B. Flores, Courtney D. DiNardo, Kapil N. Bhalla

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases